Researchers gain new clues about how to prevent aortic aneurysm in patients with Marfan syndrome

Five years ago, patients with Marfan syndrome received new hope when laboratory studies suggested that losartan, an FDA-approved drug used to treat high blood pressure, might prevent the potentially deadly enlargement of the aorta that the syndrome can cause. Now, researchers have a clearer picture of the cellular signals that contribute to progression of aortic aneurysm in Marfan syndrome and how losartan alters those signals. The new information is expected to help guide treatment decisions, as well as efforts to develop therapies that might offer benefits that losartan does not.

Read the whole article on Physorg

More from Physorg